Evicenter
MarkdownMedical informationP&T meetings
Varegacestat (AL102)

Desmoid tumors

Also known as BMS-986115
Manufacturer
Immunome
Launch
Not announced
Last updated
177 sources

Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of Desmoid tumors

Economic impact of diagnostic testing

9 evidence topics · 7 sources

Cost of centralized histological review in the French RRePS network

“A decision tree was used to assess the expected costs of two strategies of disease management: one based on revised diagnoses after centralized histological review (option 1), the other on diagnoses without centralized review (option 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The time horizon was 12 months and the perspective of the French National Health Insurance (NHI) was retained. Costs were expressed in Euros for 2013.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“A total of 2,425 patients were included. Three hundred forty-one patients (14%) had received discordant diagnoses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The probability of discordance was higher for a final diagnosis of desmoid tumors when compared to liposarcomas (odds ratio = 5.1; 95%CI [2.6–10.4]). The expected costs per patient for the base-case analysis (low- and high-case scenarios) amounted to €8,791 (€7,033 and €10,549, respectively) for option 1 and €8,904 (€7,057 and €10,750, respectively) for option 2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Centralized histological reviews are likely to provide cost-savings for the French NHI.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Concordance and 12-month management cost by initial and final diagnosis involving desmoid tumors